CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 66 enrolled
Drug / intervention
HM15211 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03744182
NCT03744182Phase 1Completed
CompareCT.gov

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD

Hanmi Pharmaceutical Company Limited·interventional·Posted Nov 16, 2018·Updated Jan 27, 2025

In Brief

A Phase 1 clinical trial evaluating HM15211 and Placebo of HM15211 for NAFLD. Completed, enrolled 66 participants across 1 site.

Detailed Summary

This study is a phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HM15211 in obese subjects with NAFLD

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNAFLD
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedNov 16, 2018
Enrollment StartNov 1, 2018
Primary CompletionMar 18, 2020
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 7.6 years ago

Interventions

HM15211drug

A sterile solution of HM15211 contained in pre-filled syringes

Placebo of HM15211drug

A sterile, matching solution in pre-filled syringes